Member Info for Cliveas

Yes it read much better than expected!

M2G now seems to be covering the cashflow needs of the company with more orders in the pipeline.

The meeting with COF in South Korea could be a defining moment in its development. You don't travel all that way to do due diligence unless you are sriously considering in investing.

Not long to wait for an update!

GL.

Beckham was already getting 15% .
Do you know the Issa bros personally.
If the sponsorship is good business for subway then it will be renewed.
If not it won't.
We shud know soon.

GL.

All buys so far!
Terms ok?
Anyone know?
Seem ok to me but wtfdik!

GL.

Bound to be some profit taking.
Fully funded until mid 2024 gives investors great reassurance.
USA insurance reimbursement set to be agreed Q2 ( Q2 on saturday!).
If I was a competitor I would be putting together a conditional bid or JV offer B4 agreed.
Last fundraise was 35p so any offer would have to be north of that imho.

GL.

Oh and one contract in the USA and boom!

GL.

Surely other government depts are going to catch on and then the wider energy market.

This could be M2G's defining moment!

GL.

M2G taking off at last and mcap is way too low.
Add some poisitive development with city oil field and a rerate is on the cards at some stage.

GL.

Jeeeze How to turn 4k into 3.3k in 40 mins Mr 25396!

Only the start of the SP recovery in my view news or JV or takeover will come soon imho.

Buy or hold but do your own research (and look at the chart).

GL.

Gotta be something brewing here!

Caredx, Natera and Eurofins have large cash balances ( from advfn) and vrci must be on the radar now!

Strategic partner or takeover take your pick!

GL.

And still a long way to go!
What value Tutivia when Moldx and medicare approval granted?
Takeover vultures circling?

GL.

Assets of 1 billion! :
Investment Overview
Empiric Student Property plc (LSE: ESP), a UK REIT, is a leading provider and operator of modern, direct-let, nominated or leased student accommodation located in prime city centre locations in top university towns and cities in the UK. The Company listed on the Main Market (Premium Listing) of the London Stock Exchange in June 2014.

Financial performance
As at 30 June 2021, the Group owned 91 assets representing 9,170 beds (31 December 2020: 9,396 beds). The portfolio included 87 revenue-generating properties at the period end, with 8,543 beds.

Property portfolio valued at £994 million at 30 June 2021 (31 December 2020: £1,005 million), reflecting the asset disposals completed. The portfolio valuation has remained stable since the year end on a like for like basis. The COVID-19 valuation deduction made by CBRE as at 30 June 2021 reduced to £20 million compared to £21.4 million at the year end.

Sustainability
We are committed to creating and operating a responsible and sustainable business which has a positive impact on all of our stakeholders. During 2020 we established a Board level ESG Committee tasked with providing a roadmap to deliver a significant step change in our approach to ESG. We will be setting out our ESG strategy in our Annual Report in March 2022.

More to come our way?!

GL.

The wider energy market is endless.
Already in one gov't dept.
Get it in the NHS! Come on RP.

GL.

Finally is the energy market actually waking up to the instant savings on energy and emissions M2G can provide?!

Also recurring income from monitoring via the cloud?!

GL.

yep news is hopefully starting to sink in.

Moldx and Medicare insurance reimbursement approval later this year (Q2) for Tutivia should be on everyones radar including competitors.

Don't rule out a takeover bid at some stage!
Oh and don't forget Clarava!
GL.

I see Anglesey has been granted Freepoert status.

I remember seeing RP with the standing MP looking at developing a site for City Oil project.

Is that all dead in the water? Surely must now be an attractive proposition.

GL.

hTTps://www.voxmarkets.co.uk/articles/q-a-with-verici-dx-ceo-sara-barrington-chief-medical-officer-dr-michael-donovan-a46755a/

GL.

Going off your 6.31 am post I'd keep quiet if I were you and read the RNS and linked in article.

All quite clear and positive after the long radio silence.

GL.

Lastly, net cash closed Dec’22 at $9.8m, providing sufficient runway until mid 2024. Whilst Singer Capital Markets are forecasting FY23 turnover of $0.9m, climbing to $6.1m in 2024, with a 79p ‘risk adjusted’ target price.

79p that'll do for me!

GL.

HTTPS://www.linkedin.com/posts/paul-hill-a5994116_vrci-vrci-vrci-activity-7044216311526125568-Rpzz?utm_source=share&utm_medium=member_desktop

"Looking ahead to the rest of the year, we plan to accelerate the rollout of Tutivia ™ to other major transplant sites throughout the US, and to secure pricing and health insurance coverage for this lead product. For Clarava ™ , we expect to report validation shortly and to initiate its initial launch before the end of the year, which will support the collation of further evidence to enable a positive coverage determination. These pivotal milestones will help refine our market positioning and further accelerate commercial uptake of both of our lead products. Verici Dx looks forward to reporting on its further progress."

Worth only 9m mcap? I think not!

GL.